Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers

• US 5,925,342 A
• Filed: 07/09/1997
• Issued: 07/20/1999
• Est. Priority Date: 11/13/1996
• Status: Expired due to Term

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan SPA (Abbvie Incorporated)
• Inventors: Kopper, Kara, Moore, Alison M., Adorante, Joseph S., WoldeMussie, Elizabeth, Ruiz, Guadalupe
• Primary Examiner(s): Azpuru, Carlos A.
• Application Number:
  US08/891,623
• Time in Patent Office: 741 Days
• Field of Search: 424/78.04, 514/912
• US Class Current: 424/78.04
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/407 condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
• CPC Class Codes: A61K 31/475 having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine vincamine A61K31/4375
• CPC Class Codes: A61K 31/49 Cinchonan derivatives, e.g. quinine
• CPC Class Codes: A61K 38/1767 from invertebrates

Abstract

Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains, as the active ingredient, one or more compounds having potassium channel blocking activity. Examples of potassium channel blockers utilized in the pharmaceutical composition and method of treatment are quinine, tremogenic indole alkaloids, such as Penitrem A and paspalicine, and insect toxins such as charybdotoxin and iberiotoxin.

Claims

1. A method for providing neuroprotective effect to the eye of a mammal in need of such treatment which comprises the step of administering to the mammal a therapeutically effective amount of a pharmaceutical composition which comprises as its active ingredient one or more compounds having potassium channel blocking activity.

2. The method of claim 1 wherein the compound having potassium channel blocking activity is selected from the group consisting of quinine, tremogenic indole alkaloids and insect toxins.

3. The method of claim 2 wherein said compound is selected from the group consisting of quinine, Penitrem A, paspalicine, charybdotoxin and iberiotoxin.

4. The method of claim 2 wherein the compound having potassium channel blocking activity is quinine.

5. The method of claim 2 wherein said compound having potassium channel blocking activity is charybdotoxin.

6. The method of claim 2 wherein the composition contains approximately 0.0001 to 1 percent weight by volume of said compound having potassium channel blocking activity.